ReviewEuropean heart journal. Imaging methods and practice2026
Quantitative imaging analysis in hypertrophic cardiomyopathy: phenotypic differentiation to prognostic stratification.
Review in European heart journal. Imaging methods and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder and remains associated with sudden cardiac death (SCD), heart failure, and diagnostic uncertainty due to overlap with other causes of left ventricular hypertrophy, including hypertensive heart disease and cardiac amyloidosis. This review aimed to evaluate the evolving applications of radiomics in the context of related quantitative imaging techniques. A review was conducted of studies applying radiomics, texture analysis, machine learning, and deep learning to cardiac imaging in HCM. The evidence base derives predominantly from CMR, with a smaller and more recent body of work in echocardiography and CT. Current evidence suggests that radiomics can extract quantitative features of myocardial texture, shape, and signal heterogeneity beyond visual assessment. These approaches have shown promise in differentiating HCM from phenocopies, identifying myocardial fibrosis without contrast administration, and improving the prediction of adverse outcomes, including SCD and heart failure. Several studies reported incremental value over conventional imaging markers such as wall thickness, global T1 values, and binary late gadolinium enhancement. However, the literature remains limited by retrospective study design, small cohorts, heterogeneity in imaging acquisition and segmentation, and insufficient external validation. Radiomics has emerged as a promising adjunct to conventional cardiac imaging in HCM, with the potential to be adapted into a clinical decision support tool. Its future clinical role will depend on methodological standardization and robust external validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.